pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Cancer Program · news · pharmadog
← back to Cancer Program
News mentioning Cancer Program
197
stories
18h
Merck gets another Phase 3 win for sac-TMT, this time in gastric cancer
endpoints
19h
Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
biospace
19h
Merck-Kelun ADC scores survival win in Phase 3 stomach cancer trial
biospace
22h
This week in charts: Biotech investors’ China bets are already paying off
biopharma dive
2d
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
2d
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
biospace
4d
Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
fiercebiotech
4d
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
biopharma dive
4d
Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
biospace
5d
Summit's PD-1xVEGF rejected by FDA in lung cancer
biospace
7d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
8d
BMS R&D head to depart amid restructure
biospace
10d
BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
fiercebiotech
10d
Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
biospace
11d
AbCellera becomes latest biotech to abandon dream of developing OX40 drug
fiercebiotech
11d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
14d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
14d
Moderna enjoys stable vaccine sales thanks to global COVID uptake
biospace
14d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
14d
Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market
biospace
15d
Moderna’s norovirus vaccine plans in limbo in wake of phase 3 miss
fiercebiotech
15d
Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweights
fiercebiotech
15d
Merck abandons Sutro-partnered IL-2 drug in ‘routine pipeline prioritization’
fiercebiotech
15d
Revolution’s Rasonque off to best cancer drug launch ‘in history’
biopharma dive
16d
Alethio clinches $90M to advance antibody for essential thrombocythemia
endpoints
17d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
18d
AbbVie abandons phase 2 solid tumor drug over ‘limited benefit’
fiercebiotech
18d
Keytruda biosimilars are coming — but they face an uphill battle
biopharma dive
19d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
21d
This week in charts: ESMO’s winners and losers
biopharma dive
← prev
page 1 of 7
next →